Back to Back Issues Page
New FDA Approved Susvimo for AMD Treatment
November 10, 2021
Hello

New FDA Approved Susvimo for AMD Treatment

The newly FDA approved Susvimo treatment for wet macular degeneration will provide a continuous delivery of anti-VEGF medicine of ranibizumab (Lucentis) via a refillable implant over a 6 month period.  The implant will be refilled every 6 months and provides a welcome relief from regular frequent eye injections.  Based on the recently published positive results from the ARCHWAY phase 3 study, eyes treated with the port delivery system gained an average of 0.2 letters in visual acuity.


“Susvimo represents a major advancement in the treatment of retinal disease, and is an important new option for patients with wet AMD,” Ocular Surgery News Editorial Board Member Carl D. Regillo, MD, chief of retina service at Wills Eye Hospital, said in the release. “With Susvimo, my patients now have an option that can help them maintain their vision as well as anti-VEGF injections, but on a more manageable twice-yearly treatment schedule.”

Find out more about Susvimo and watch a short video on how it works here....

Recently FDA Approved Susvimo Port Delivery System

Leslie Degner, RN, BSN

Better Health for Better Vision

www.WebRN-MacularDegeneration.com

Back to Back Issues Page